Vaccine-Induced Memory CD8⁺ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study.

ABSTRACT:

Purpose

Immune-based therapy for metastatic breast cancer has had limited success, particularly in molecular subtypes with low somatic mutations rates. Strategies to augment T-cell infiltration of tumors include vaccines targeting established oncogenic drivers such as the genomic amplification of HER2. We constructed a vaccine based on a novel alphaviral vector encoding a portion of HER2 (VRP-HER2).

Patients and methods

In preclinical studies, mice were immunized with VRP-HER2 before or after implantation of hHER2⁺ tumor cells and HER2-specific immune responses and antitumor function were evaluated. We tested VRP-HER2 in a phase I clinical trial where subjects with advanced HER2-overexpressing malignancies in cohort 1 received VRP-HER2 every 2 weeks for a total of

SUBMITTER: Crosby EJ 

PROVIDER: S-EPMC6497539 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature